SGK3 and breast carcinoma: Similarly, PROTACs using biochemical inhibitors were designed to tag SGK3 kinase with VHL ubiquitin ligases to facilitate selective and efficient degradation of SGK3 in breast cancers compared to conventional inhibitors because of their sub-stoichiometric catalytic mode of action (Tovell et al., 2019).